Literature DB >> 9127177

Multimodal therapies in ductal pancreatic cancer. The future.

K H Link1, F Gansauge, J Pillasch, H G Beger.   

Abstract

CONCLUSIONS: Intra-arterial infusion chemotherapy via the celiac axis combined with external beam radiotherapy might be an effective method for palliative and perioperative multimodal treatment in pancreatic cancer. To improve the dismal prognosis in resectable and nonresectable pancreatic cancer, the results of multimodal palliative, adjuvant, and neoadjuvant therapies were reviewed and put into perspective with the results of two intra-arterial palliative and adjuvant treatment studies conducted at our department. The benefits and pitfalls of each method were outweighed, resulting in a concept for performing intra-arterial chemotherapy with radiotherapy in nonresectable stage UICC-III pancreatic cancer that eventually will be developed as a combined neoadjuvant/adjuvant treatment of all potentially resectable ductal pancreatic carcinomas.

Entities:  

Mesh:

Year:  1997        PMID: 9127177     DOI: 10.1007/BF02785923

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  58 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma.

Authors:  M Di Bartolomeo; M G Zampino; A Di Leo; E Bajetta
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 3.  Overview of chemotherapy for pancreatic cancer.

Authors:  S G Arbuck
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

4.  Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil.

Authors:  M L Foo; L L Gunderson; D M Nagorney; D C McLlrath; J A van Heerden; J S Robinow; L K Kvols; G R Garton; J A Martenson; S S Cha
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-06-15       Impact factor: 7.038

5.  Treatment perspectives in locally advanced unresectable pancreatic cancer.

Authors:  J Jeekel; A D Treurniet-Donker
Journal:  Br J Surg       Date:  1991-11       Impact factor: 6.939

6.  A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.

Authors:  M Büchler; H Friess; K H Schultheiss; C Gebhardt; R Kübel; K H Muhrer; M Winkelmann; T Wagener; R Klapdor; M Kaul
Journal:  Cancer       Date:  1991-10-01       Impact factor: 6.860

7.  Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.

Authors:  P H Sugarbaker; F J Gianola; J L Speyer; R Wesley; I Barofsky; C E Myers
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

8.  Application of theoretical models to chemotherapy protocol design.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1986-01

9.  Implications of peritoneal cytology for staging of early pancreatic cancer.

Authors:  A L Warshaw
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

10.  Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery.

Authors:  H Baumel; M Huguier; J C Manderscheid; J M Fabre; S Houry; H Fagot
Journal:  Br J Surg       Date:  1994-01       Impact factor: 6.939

View more
  7 in total

Review 1.  Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer.

Authors:  D Birk; H G Beger
Journal:  Curr Gastroenterol Rep       Date:  2001-04

Review 2.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

4.  Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.

Authors:  C Zanon; O Alabiso; M Grosso; R Buosi; I Chiappino; R Clara; A Satolli; S Zai; M Bortolini; M Botta; A Mussa
Journal:  Int J Pancreatol       Date:  2000-06

5.  Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum.

Authors:  M Kornmann; N Arber; M Korc
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

6.  Results of regional chemotherapy using the aortic stop-flow technique in advanced pancreatic carcinoma.

Authors:  Frank Meyer; Thomas Gebauer; Reinhard Grote; Jens Martens-Lobenhoffer; Karsten Ridwelski; Hans Lippert
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

7.  Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells.

Authors:  Koji Hashimoto; Richard T Ethridge; B Mark Evers
Journal:  Int J Gastrointest Cancer       Date:  2002
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.